$-0.08 EPS Expected for Cumberland Pharmaceuticals Inc. (CPIX)

August 9, 2018 - By Megan Stone

Investors sentiment decreased to 0.69 in Q1 2018. Its down 0.17, from 0.86 in 2017Q4. It is negative, as 4 investors sold Cumberland Pharmaceuticals Inc. shares while 9 reduced holdings. 1 funds opened positions while 8 raised stakes. 4.09 million shares or 0.64% less from 4.12 million shares in 2017Q4 were reported.
Ariel Invests Llc holds 1.01 million shares. Bard Associates Inc invested in 0.28% or 83,215 shares. Sei Invests Co has invested 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Vanguard Group Incorporated has invested 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). State Street holds 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) or 11,258 shares. Dimensional Fund Advisors Limited Partnership owns 883,085 shares. Acadian Asset Limited Liability Company owns 107,322 shares. Morgan Stanley, a New York-based fund reported 20,415 shares. Renaissance Techs owns 353,500 shares. California Pub Employees Retirement Systems invested in 0% or 53,800 shares. Geode Mgmt Limited Liability accumulated 48,610 shares or 0% of the stock. Ny State Common Retirement Fund has 260,730 shares. Jw Asset Mgmt Ltd Com stated it has 1.18% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Prudential Fincl stated it has 20,600 shares. Spark Inv Limited Liability holds 0% or 10,800 shares.

Since March 19, 2018, it had 2 buys, and 0 selling transactions for $4,464 activity.

Analysts expect Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) to report $-0.08 EPS on August, 14.They anticipate $0.01 EPS change or 14.29 % from last quarter’s $-0.07 EPS. After having $-0.11 EPS previously, Cumberland Pharmaceuticals Inc.’s analysts see -27.27 % EPS growth. The stock decreased 2.21% or $0.13 during the last trading session, reaching $5.74. About 1,111 shares traded. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has declined 14.79% since August 9, 2017 and is downtrending. It has underperformed by 27.36% the S&P500.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Ratings Coverage

Among 2 analysts covering Cumberland (NASDAQ:CPIX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cumberland had 2 analyst reports since April 17, 2018 according to SRatingsIntel. FBR Capital initiated the stock with “Buy” rating in Tuesday, April 17 report.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. The company has market cap of $90.18 million. It marketed products include Acetadote injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. It currently has negative earnings. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.